体内BCR::ABL1阴性的慢性髓增殖性肿瘤（MPNs）患者心血管（CV）风险因素的确切预后作用目前尚不清楚，因为常常被其他MPN相关特征所掩盖，而这些特征对血栓风险具有强烈的预后影响。因此，目前的MPN治疗不是主要以CV风险因素的存在为指导。MPN患者的CV风险因素治疗通常与一般人群相似，尽管MPN患者的CV风险因素具有其自身的特殊性。此外，MPN中不同代谢偏差的最佳目标水平（如低密度脂蛋白、血清尿酸或糖化血红蛋白水平）尚未定义。在本综述中，我们分别讨论MPN中每个个体CV风险因素（动脉高血压、高脂血症、慢性肾脏疾病、吸烟、糖尿病、高尿酸血症以及肥胖和消瘦），总结了该领域的最新进展，并提出了未来的方向和研究领域，以便恰当地管理MPN中的CV风险因素。© 2023. 作者（们）在 Springer-Verlag GmbH Germany，即 Springer Nature 的专属许可下。

The exact prognostic role of cardiovascular (CV) risk factors in patients with BCR::ABL1 negative chronic myeloproliferative neoplasms (MPNs) remains unknown as it is often masked by other MPN-related features that bear strong prognostic impact on thrombotic risk. Therefore, current MPN treatment is not primarily guided by presence of CV risk factors. Treatment of CV risk factors in MPN patients usually mirrors that from the general population, despite the fact that CV risk factors in MPNs have their own specificities. Moreover, the optimal target levels for different metabolic deflections in MPNs (i.e., low-density lipoprotein, serum uric acid, or glycated hemoglobin levels) have not been defined. In the current review, we separately discuss the most important aspects of every individual CV risk factor (arterial hypertension, hyperlipidemia, chronic kidney disease, smoking, diabetes mellitus, hyperuricemia, and obesity and cachexia) in MPNs, summarize recent advances in the field, and propose future directions and research areas which may be needed to appropriately manage CV risk factors in MPNs.© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany, part of Springer Nature.